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Patients with inflammatory bowel disease are at increased risk for colon cancer due to augmented oxidative stress. These
patients also have compromised antioxidant defenses as the result of nutritional deficiencies. The micronutrient selenium
is essential for selenoprotein production and is transported from the liver to target tissues via selenoprotein P (SEPP1).
Target tissues also produce SEPP1, which is thought to possess an endogenous antioxidant function. Here, we have shown
that mice with Sepp1 haploinsufficiency or mutations that disrupt either the selenium transport or the enzymatic domain of
SEPP1 exhibit increased colitis-associated carcinogenesis as the result of increased genomic instability and promotion of a
protumorigenic microenvironment. Reduced SEPP1 function markedly increased M2-polarized macrophages, indicating a role
for SEPP1 in macrophage polarization and immune function. Furthermore, compared with partial loss, complete loss of SEPP1
substantially reduced tumor burden, in part due to increased apoptosis. Using intestinal organoid cultures, we found that,
compared with those from WT animals, Sepp1-null cultures display increased stem cell characteristics that are coupled with
increased ROS production, DNA damage, proliferation, decreased cell survival, and modulation of WNT signaling in response
to H2O2-mediated oxidative stress. Together, these data demonstrate that SEPP1 influences inflammatory tumorigenesis by
affecting genomic stability, the inflammatory microenvironment, and epithelial stem cell functions.

Introduction

Inflammatory bowel disease (IBD) primarily comprises two
types of chronic inflammatory disorders of the intestine:
Crohn’s disease and ulcerative colitis. IBD affects approximately 1.4 million Americans, with typical onset occurring at
between 15 and 30 years of age (1). While the etiology of IBD is
incompletely understood, prevailing thought presents a model
in which the interplay of (a) intestinal microbiota or other undefined environmental exposures, (b) genetic susceptibility, and
(c) inappropriately sustained and severe autoimmune inflammatory responses leads to repetitive injury of the GI tract,
resulting in a protumorigenic microenvironment rich in ROS
and reactive nitrogen species that predisposes to colon cancer
(2, 3). Colitis-associated cancer (CAC) risk in IBD is influenced
by several factors, including age of diagnosis, disease extent,
and severity of inflammation (4–8). Importantly, as increased
disease activity is associated with increased cancer risk, understanding modifiers of IBD severity and CAC risk factors is of
paramount importance.
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Selenium is a trace element that is specifically incorporated
into selenoproteins as selenocysteine through a specialized
UGA codon encoded in the mRNA. Selenium deficiency results
in stimulation of the WNT and NRF2 pathways (9–11), which
are both heavily implicated in the pathogenesis of colon cancer
(12–14). Selenoproteins are enzymes that participate in oxidative
defense and are thought to protect against colon cancer, especially in settings of high oxidant stress, such as chronic inflammatory states. Several epidemiological studies have inversely
correlated nutritional selenium status and cancer risk, particularly in colon cancer (15). Recently, our laboratory has demonstrated that selenium deficiency in mice exacerbates intestinal
injury in response to chemical models of colitis and increases
tumorigenesis in CAC modeling (16).
Selenoprotein P (SEPP1) is a major selenoprotein and is
thought to serve two main roles: supplying tissues with selenium
and acting in an antioxidant defense capacity. The transport
role is carried out by the C-terminal domain of SEPP1, which
contains 9 selenocysteine residues (17, 18). The antioxidant role
is carried out by a single selenocysteine within a UXXC redox
motif at amino terminal residues 40–43 (19), a domain that has
recently been shown to have peroxidase activity (20). As selenoproteins are produced in a hierarchical manner based on selenium availability, the importance of SEPP1 is underscored by the
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fact that, even under conditions of severe selenium deficiency,
its production perseveres (19). Previous studies have shown that
SEPP1 is downregulated in colorectal cancers (CRCs) (21) and
SNPs within the gene are associated with advanced adenoma
risk (22). Because SEPP1 serves as the major selenium transport
protein, the known effects of selenium on WNT and NRF2 signaling in target tissues may partially depend on SEPP1. The antioxidant function of SEPP1 also suggests that it could play a role
in cancer prevention, particularly in the context of inflammatory cancers characterized by increased oxidative stress, such
as CAC (23). Indeed, the gastrointestinal tract is susceptible to
oxidative damage resulting from direct contact of the colonic
epithelium with microbial and food-derived ROS, and the loss
of SEPP1 might result in increased oxidative damage–induced
tumor initiation in the colonic mucosa. This potential damage is
augmented in the context of IBD, during which oxidative stress
plays a major role (23). Thus, SEPP1 may regulate stem cell pathways and protect from CAC.
In the present study, we investigated the role of SEPP1 in
colonic epithelial biology and how its loss affects colitis-associated carcinoma. We demonstrate that SEPP1 loss contributes to
increases in colonic epithelial stem cell properties and modulation of WNT tone and, in response to oxidative stress, decreases
cell survival and increases oxidative DNA damage in intestinal
organoids. These SEPP1-dependent phenotypes ultimately contribute to an increase in inflammatory tumorigenesis with Sepp1
heterozygosity or upon loss of either the redox-active site or the
selenium transport domain of SEPP1. SEPP1 manipulation was
found to alter the tumor microenvironment and genomic integrity. Our findings establish a critical role for SEPP1 in intestinal
biology, homeostasis, injury response, preservation of genomic
integrity, and inflammatory carcinogenesis.

Results

Loss of SEPP1 enhances both tumor promotion and initiation.
Because SEPP1 mRNA expression is decreased as early as the
adenoma stage in CRC (ref. 24 and Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/
JCI76099DS1) and in tumors of mice subjected to an inflammatory carcinogenesis protocol (Supplemental Figure 1B), we predicted that SEPP1 loss would enhance tumorigenesis. In order
to test the impact of SEPP1 loss on tumor initiation and promotion, respectively, we used both a 6-month azoxymethane (AOM)
protocol (Figure 1A) and a chronic dextran sodium sulfate (DSS)
administration protocol (Figure 1B). AOM is a procarcinogen
that is metabolically activated to a potent alkylating agent forming O6-methyl-guanine (25). DSS serves as a tumor-promoting
agent, and repeated DSS administration produces chronic colonic
inflammation (26). To determine whether SEPP1 deletion influences colonic tumorigenesis, we used Sepp1–/– mice. These mice
are globally null for SEPP1, and a lack of expression could be seen
in both the Sepp1–/– colon and small intestine as compared with
WT mice (Figure 1C). Methylene blue staining of colons 6 months
after AOM administration revealed an increase in aberrant crypt
foci (ACF) in Sepp1–/– mice compared with that in WT mice (6.0 ±
0.6 vs. 2.5 ± 0.3 ACF per colon, P < 0.001; Figure 1D), indicating a
role for SEPP1 loss in tumor initiation. Endoscopic injury analysis

Research article

of mice subjected to chronic DSS administration using the murine
endoscopic index of colitis severity (MEICS) scoring system (27)
revealed increased injury in response to DSS after 3 cycles (8.1 ±
0.4 vs. 4.1 ± 0.5 MEICS score, P < 0.0001; Figure 1E). Furthermore,
chronic DSS treatment led to increased ACF formation in Sepp1–/–
mice compared with that in both WT and Sepp1+/– mice (Sepp1–/–,
3.2 ± 0.4 in tumors per colon vs. Sepp1+/–, 2.1 ± 0.3, and WT, 1.9 ±
0.3 tumors per colon, P < 0.05; Figure 1E), suggesting that complete SEPP1 loss exacerbates injury and tumorigenesis in response
to DSS. In addition, Sepp1–/– mice demonstrated decreased proliferation after chronic DSS treatment in comparison with that of
Sepp1+/– and WT mice (Figure 1E), with no differences in apoptosis
(data not shown) among the cohorts.
SEPP1 is a haploinsufficient tumor suppressor in inflammatory
carcinogenesis. Based on the impact of SEPP1 loss on initiation
in response to AOM and DSS as single modalities, we predicted
that SEPP1 would play a critical role in ensuring tumor cell survival after inflammatory injury. We used a CAC model in which
WT, Sepp1+/–, and Sepp1–/– mice received AOM and repeated-dose
DSS (AOM/DSS). As expected, complete loss of SEPP1 decreased
colonic selenium content (Figure 2A), though we noted that this
decrease was modest, indicating that SEPP1 is not the only mechanism of selenium supply in the colon. Complete loss of SEPP1 led
to a decrease in tumor multiplicity (2.7 ± 0.7 in Sepp1–/– vs. 5.2 ± 0.8
tumors per mouse in WT, P = 0.02; Figure 2, B and C) and alteration in tumor size in Sepp1–/– mice compared with that in Sepp1+/–
mice but not WT mice (2.5 ± 0.4 in Sepp1–/– vs. 4.2 ± 0.5 mm2 in
Sepp1+/–, P = 0.01; Figure 2, B and D), suggesting that complete loss
of SEPP1 impaired survival or proliferation of initiated epithelial
cells. In contrast, partial loss of SEPP1 led to increased tumor multiplicity (8.3 ± 1.2 in Sepp1+/– vs. 5.2 ± 0.8 tumors per mouse in WT,
P = 0.03; Figure 2, B and C) but no change in tumor size. However,
histopathological examination suggested more advanced dysplasia in the Sepp1+/– mice (Figure 2E).
The decrease in tumorigenesis in the Sepp1–/– mice was concomitant with increased apoptosis, as measured by TUNEL staining (74.4 ± 10.9 vs. 34.3 ± 3.1 TUNEL+ cells per tumor high-power
field [HPF] in WT, P < 0.01; Figure 3A, left, and Supplemental Figure 2, A and B, top) and Western blotting for markers within the
intrinsic apoptosis pathway (Figure 3A and Supplemental Figure
2B, bottom). Therefore, we hypothesized that decreased tumor
multiplicity might be caused in part by clearance of initiated cells
due to oxidative injury beyond that which total SEPP1 loss can
compensate. This phenomenon has been hypothesized to play
a role in the initiation process of many cancers and was recently
demonstrated in the process of ferroptosis, a mechanism of cell
death triggered via the production of iron-dependent ROS (28,
29). Moreover, proliferation was increased in Sepp1+/– tumors (85.9
± 2.9 vs. 55.6 ± 2.8 Ki67+ cells per tumor HPF in WT, P < 0.0001;
Figure 3B and Supplemental Figure 2D) and decreased in Sepp1–/–
tumors (19.0 ± 6.9 vs. 55.6 ± 2.8 Ki67+ cells per tumor HPF in WT,
P < 0.0001; Figure 3B and Supplemental Figure 2D) and crypts
(1.6 ± 0.2 vs. 4.6 ± 0.2 Ki67+ cells per crypt in WT, P < 0.0001; Supplemental Figure 2C). These data support a role for clearance of
initiated cells in Sepp1–/– tumors.
Intratumoral DNA damage increases in a dose-dependent
manner with decreased SEPP1 levels. Selenium has been identijci.org   Volume 125   Number 7   July 2015
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Figure 1. Absence of SEPP1 exacerbates tumorigenesis in response to AOM and injury after chronic DSS treatment. (A) Schematic of the AOM protocol
used. Mice were injected with AOM and aged for 6 months before being sacrificed on day 180 after AOM treatment. (B) Schematic of the chronic DSS
protocol used. Mice were subjected to three 5-day cycles of 3% DSS ad libitum. There were 16 days of recovery between each DSS administration, and
mice were monitored for injury by endoscopy (black circles) 4 days after each DSS cycle (gray rectangles). (C) Immunofluorescent staining of SEPP1 (red)
within the colons and small intestines of WT and Sepp1–/– mice (original magnification, ×100). (D) ACF counts per mouse in WT (n = 4), Sepp1+/– (n = 4),
and Sepp1–/– (n = 3) mice subjected to the AOM protocol. (E) Endoscopic colitis score, ACF counts, and Ki67 staining in mice subjected to the chronic DSS
protocol (7, WT; 10, Sepp1+/–; 10, Sepp1–/–). *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA, Newman-Keuls multiple comparison test.

fied as a potential contributor to the maintenance of genomic
stability (30, 31). However, the role of SEPP1 in DNA damage
repair is unknown. We wanted to test the impact of SEPP1 deficiency on crypt and intratumoral DNA damage. 8-hydroxyguanine (8-OHdG) staining, a measure of oxidative DNA damage,
demonstrated that intratumoral DNA damage increases with
decreased Sepp1 expression (WT: 8.1 ± 0.8 8-hydroxyguanine+
cells per tumor HPF, Sepp1+/–: 15.3 ± 1.5, 8-hydroxyguanine+ cells
per tumor HPF, P = 0.002; Sepp1–/–: 23.3 ± 3.4 8-hydroxyguanine+
cells per tumor HPF, P = 0.0007; Figure 3C and Supplemental
Figure 2F), though crypt DNA damage was not altered when
compared with that of WT mice in response to SEPP1 deficiency
(Supplemental Figure 2E). These data suggest that, within the
2648
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tumor microenvironment, decreasing Sepp1 expression leads to
an increase in oxidative DNA damage.
Protumorigenic M2 macrophage polarization is increased in
Sepp1+/– tumors. The most significantly induced gene after polarization of macrophages to the M2 phenotype is SEPP1 (32–34).
Moreover, proinflammatory cytokines induce iNOS, which results
in downregulation of SEPP1 (35). To determine whether SEPP1
influences macrophage phenotypes and inflammation, we analyzed tumors from WT, Sepp1+/–, and Sepp1–/– mice after AOM/DSS
treatment for macrophage polarization. Immunohistochemistry of
tumors for the pan-macrophage marker F4/80 and either the M1
macrophage marker IL-1β or the M2 macrophage marker arginase I (Arg1) revealed an increase of total macrophages in Sepp1+/–
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Figure 2. Sepp1 haploinsufficiency augments inflammatory carcinogenesis. (A)
Quantification of colonic selenium in WT
(n = 8), Sepp1+/– (n = 5), and Sepp1–/– (n = 8)
mice fed a selenium-supplemented (1.0
PPM) diet. (B) Representative gross colon
images. (C) Tumor number (tumors per
mouse) and (D) average tumor size (mm2)
per mouse (17, WT; 15, Sepp1+/–; 20, Sepp1–/–).
(E) Representative images of Swiss-rolled
colons from each genotype (original magnification, ×25). Scale bar: 500 μm. *P < 0.05,
**P < 0.01, ***P < 0.001, 1-way ANOVA,
Newman-Keuls multiple comparison test.

tumors (WT: 13.1 ± 1.3, Sepp1+/–: 23.2 ± 3.0, P < 0.01, Sepp1–/–: 13.1
± 0.8 F4/80+ cells per tumor HPF; Figure 4A), apparently resulting from an increased M2 macrophage presence (WT: 8.4 ± 0.8,
Sepp1+/–: 18.0 ± 3.9, Sepp1–/–: 8.3 ± 1.1 F4/80+/ARG1+ cells per tumor
HPF; Figure 4C), as M1 macrophage numbers remain unaltered
(Figure 4B). Interestingly, Sepp1–/– tumors did not demonstrate
increased M2 polarized macrophage infiltration. In order to determine whether this effect was due to recruitment or polarization, we
isolated bone marrow macrophages from WT, Sepp1+/–, and Sepp1–/–
mice and treated them with IFN-γ and LPS to polarize to the M1
phenotype and IL-13 to polarize to the M2 phenotype. Analysis of
M1 markers Inos and Il1b demonstrated decreased M1 polarization
in Sepp1+/– macrophages (Inos: 19,494 ± 593.8 vs. 14,961 ± 782.3 fold
change, P < 0.001; Il1b: 337.6 ± 0.78 vs. 225.1 ± 20.66 fold change,
P < 0.001; Figure 4D), while the M2 marker Ym1 indicated increased
polarization to M2 (13.1 ± 3.3 vs. 26.6 ± 0.3, P < 0.001; Figure 4E).
These data indicate that Sepp1 haploinsufficiency leads to altered
macrophage polarization upon directed stimulation, a phenotype
observed in vivo in the inflammatory infiltrates in Sepp1+/– tumors.
Therefore, it is possible that altered immune responses may con-

tribute to a protumorigenic microenvironment in these mice.
Loss of the selenium-rich C-terminal
domain of SEPP1 promotes inflammatory tumorigenesis. SEPP1 is considered
to be a selenium transport protein, and
deletion of the selenium-rich C-terminal domain (Sepp1Δ240–361/Δ240–361) results
in severe selenium deficiency in the
brain and testes of mice (36). Colonic
selenium levels were also decreased in
Sepp1Δ240–361/Δ240–361 mice (394.5 ± 19.6
vs. 260.2 ± 10.6 ng selenium/g colon,
P = 0.0001; Figure 5A), yet the presence
of selenium suggests that, while SEPP1
contributes to selenium delivery to the
colon, it is not the sole source. Because
selenium has been implicated in DNA
damage repair via regulation of p53 (37),
WNT and NRF2 signaling, and modification of several cancer types, including
colorectal, lung, laryngeal, hepatic, and
prostate (38–41), we determined whether
the loss of the selenium-rich domain of SEPP1 would contribute to
tumorigenesis. We subjected WT and Sepp1Δ240–361/Δ240–361 mice to the
AOM/DSS protocol and analyzed them for tumor burden. We found
that SEPP1 truncation resulted in an increase in tumor number (7.9
± 1.4 vs. 3.9 ± 0.7 tumors per mouse, P = 0.02; Figure 5B). We have
previously determined that selenium deficiency results in increased
dysplasia grade in this model (16). Similarly, tumor grade was more
advanced in Sepp1Δ240–361/Δ240–361 mice (P < 0.05; Figure 5C).
Along with an increase in tumor number, we also observed an
increase in intratumoral proliferation (20.3 ± 2.2 vs. 13.4 ± 1.7 Ki67+
cells per tumor HPF, P = 0.04; Figure 5D and Supplemental Figure
3A) but no change in crypt proliferation (Supplemental Figure 5A) or
crypt or tumor apoptosis (Supplemental Figure 4, B and C). Consistent with a role of selenium in DNA damage, there was an increase
in crypt (1.0 ± 0.08 vs. 0.7 ± 0.04 8-OHdG+ cells per crypt, P = 0.02;
Figure 5E and Supplemental Figure 3B) and intratumoral (29.8 ± 2.8
vs. 17.1 ± 2.7 8-OHdG+ cells per tumor HPF, P = 0.01; Figure 5F and
Supplemental Figure 3C) DNA damage index scores in mice lacking
the selenium-rich C-terminal domain compared with that in WT
mice. These data suggest that the selenium-rich domain of SEPP1
jci.org   Volume 125   Number 7   July 2015
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Figure 3. Intratumoral apoptosis and DNA damage are increased in response to complete Sepp1 knockout, and proliferation is increased in Sepp1+/–
tumors. (A) Quantification of intratumoral apoptosis, as determined by TUNEL+ cells per tumor HPF (original magnification, ×40; 6, WT; 10, Sepp1+/–; 4
Sepp1–/–), and quantification of cleaved caspase-3 protein normalized to caspase-3 and cleaved PARP protein normalized to β-actin. Quantification is shown
as fold change relative to WT (n = 6 per group). (B) Quantification of intratumoral proliferation, as determined by Ki67+ cells per tumor HPF (6, WT; 10,
Sepp1+/–; 4, Sepp1–/–). (C) Quantification of intratumoral DNA damage, as measured by 8-hydroxyguanine+ cells per tumor HPF (6, WT; 10, Sepp1+/–; 4 Sepp1–/–).
*P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA, Newman-Keuls multiple comparison test.

may protect from tumor initiation by preserving genomic integrity.
Mutation of the redox-active selenocysteine in SEPP1 promotes
inflammatory tumorigenesis. Residues 40–43 of the N-terminal
domain of SEPP1 comprise a UXXC redox motif that acts as a peroxidase (19, 20). As such, SEPP1 may contribute to antioxidant
activity independent of its roles in selenium transport. In order to
test whether loss of this antioxidant domain would modify tumorigenesis, we subjected mice in which the selenocysteine (U) at
amino acid 40 was mutated to an enzymatically dead serine (S)
(Sepp1U40S/U40S) to the AOM/DSS protocol. Compared with those in
WT mice, SEPP1-mutated mice displayed increased tumor number (7.3 ± 1.1 vs. 3.8 ± 0.7 tumors per mouse, P = 0.02; Figure 5G)
and tumor size (3.1 ± 0.3 vs. 1.6 ± 0.2 mm2, P = 0.002; Figure 5H).
This increase in tumorigenesis was likely at least partially dependent upon an increase in crypt proliferation (0.5 ± 0.04 vs. 0.3 ±
0.02 Ki67+ cells per crypt, P = 0.0009; Figure 5I and Supplemental
Figure 5A) and intratumoral proliferation (33.5 ± 2.6 vs. 15.2 ± 1.6
Ki67+ cells per tumor HPF, P < 0.0001; Figure 5J and Supplemental Figure 5B), compared with those in WT mice, despite a lack
of change in apoptosis (Supplemental Figure 6, A and B). We did
note an increase in crypt DNA damage (0.6 ± 0.02 vs. 0.3 ± 0.03
8-OHdG+ cells per crypt, P < 0.0001; Figure 5K and Supplemental
Figure 5C) and intratumoral DNA damage (28.7 ± 2.6 vs. 10.8 ±
1.2 8-OHdG+ cells per tumor HPF, P < 0.0001; Figure 5L and Supplemental Figure 5D) in the SEPP1-mutated mice compared with
2650
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those in WT mice, suggesting that the redox site of SEPP1 contributes to protection from DNA damage.
Sepp1 haploinsufficiency-driven CAC persists in mice fed normal selenium diets. Sepp1–/– mice require selenium supplementation to survive (42); therefore, all of the above experiments were
conducted in the setting of supranutritional selenium levels. Our
results indicate that Sepp1 haploinsufficiency augments tumorigenesis. We next determined whether Sepp1 heterozygosity would also
augment tumorigenesis if mice were maintained on a normal selenium diet (0.25 PPM selenium). Compared with WT mice, Sepp1+/–
mice demonstrated an increase in tumor number, as determined by
both endoscopy (9.8 ± 1.2 vs. 4.6 ± 0.8 tumors per mouse, P < 0.01;
Figure 6, A and B) and analysis of tumor burden at sacrifice (11.6 ±
1.0 vs. 5.5 ± 0.9 tumors per mouse, P < 0.001; Figure 6, C and D),
and, in general, these tumors were also larger than those observed
in WT colons (P < 0.05; Figure 6E). When comparing overall survival of cohorts maintained on a normal selenium diet (0.25 PPM
selenium) with that of those on a selenium-supplemented diet
(1.0 PPM selenium), cohorts maintained on the selenium-supplemented diet demonstrated a significant survival benefit (P < 0.001;
Figure 6F). These results may have potential translational implications, as the 0.25 PPM diet more closely approximates selenium
levels in the typical Western diet.
Absence of SEPP1 augments stem cell properties and reduces the
ability of enteroids to survive in response to hydrogen peroxide. SEPP1
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Figure 4. SEPP1 regulates protumorigenic M2 macrophage polarization. Quantification of (A) intratumoral total macrophage staining, as determined by
F4/80+ cells per tumor HPF; (B) M1 macrophage staining, as determined by F4/80+/IL-1β+ cells per tumor HPF; and (C) M2 macrophage staining, as determined
by F4/80+/ARG1+ cells per tumor HPF (8, WT; 12, Sepp1+/–; 8, Sepp1–/–). (D) Inos (n = 5 per genotype) and Il1b (n = 6 per genotype) and (E) Ym1 mRNA expression
(n = 6 per group) in WT, Sepp1+/–, and Sepp1–/– in vitro–activated bone marrow macrophages. Graphs demonstrate fold change in expression relative to unstimulated (US) WT macrophages normalized to Gapdh. *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA, Newman-Keuls multiple comparison test.

regulates oxidative stress and toxicity (43, 44) and, consistent with
a function in WNT signaling, has been shown to play a role in differentiation and stem cell properties (45, 46). Recently, a model for
epithelial crypt growth has been established based on the isolation
of stem cells from the small intestinal crypt. From single crypts,
complex structures can be grown in vitro that closely resemble their
ex vivo counterparts (enteroids) (47). Using this model system,
we sought to determine how SEPP1 influences intestinal epithelial biology. Importantly, Sepp1 expression in intestinal organoids
was similar to expression in both the colon and the brain, a tissue
known to produce high levels of SEPP1 (48), indicating these cultures would accurately recapitulate an in vivo setting (Figure 7A).
Enteroids can be grown from a single stem cell or complete
crypts (49), and the “stemness” of enteroids has been measured
by several growth parameters (50–52). For instance, augmented
stem cell survival can be measured by an increase in the number of
crypts that survive plating versus the total number of crypts plated
(plating efficiency). Furthermore, the percentage of branching
enteroids or stem spheroids present at certain time points can
establish the differentiation capacity of the stem cells and the
extent of stem cell signaling, respectively. Finally, the number of
branches within each enteroid indicates the ability of the stem cells
to self-propagate and establish new crypts. To determine whether
Sepp1 contributes to epithelial cell growth and stem cell function
at baseline, we analyzed Sepp1–/– enteroids for each of these properties (plating efficiency: 96.5% ± 2.4% enteroids of total crypts
plated; 61.5% ± 1.8% branching enteroids; 14.5% ± 0.2% stem
spheroids; 3.2 ± 0.2 number of branches per branching enteroid;

Figure 7B) and observed increased stem cell fitness and growth
abilities compared with those of WT enteroids (plating efficiency:
65.5% ± 2.0% enteroids of total crypts plated, P < 0.0001; 42.1% ±
2.4% branching enteroids, P = 0.02; 7.6% ± 0.9% stem spheroids,
P = 0.002; number of branches per branching enteroid: 1.9 ± 0.1,
P = 0.003; Figure 7B).
Because SEPP1 serves as a peroxidase in vitro (20), we next
determined the response of Sepp1–/– enteroids to hydrogen peroxide treatment. Analysis of ROS produced after treatment with
hydrogen peroxide revealed a decreased ability of Sepp1–/– small
intestine to respond to oxidative stress, as demonstrated by
increased 6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate
(carboxy-H2DCFDA) staining intensity (800 μM H2O2: 1.6 ± 0.4 vs.
3.3 ± 0.4 fold change intensity relative to 0 μM H2O2 WT, P = 0.04;
Figure 7C); however, there was no change in staining intensity
of the oxidative-insensitive analog carboxy-DCFDA. Moreover,
baseline proliferation was increased in Sepp1–/– enteroids (1.0 ±
0.06 vs. 1.4 ± 0.1 fold change EdU+ cells per crypt area relative to 0
μM H2O2 WT, P < 0.05; Figure 7D) and, while treatment with hydrogen peroxide resulted in decreased Sepp1–/– proliferation compared
with that of untreated null enteroids (1.4 ± 0.1 vs. 0.9 ± 0.09 fold
change EdU+ cells per crypt area relative to 0 μM H2O2 Sepp1–/–,
P < 0.01; Figure 7D), Sepp1–/– enteroids retained increased proliferation compared with that of WT enteroids (0.4 ± 0.09 vs. 0.9 ±
0.09 fold change EdU+ cells per crypt area relative to 0 μM H2O2
WT, P < 0.05; Figure 7D). Finally, Sepp1–/– enteroids demonstrated
decreased survival in response to multiple daily administrations of
hydrogen peroxide (P = 0.005; Figure 7E). These data indicate that
jci.org   Volume 125   Number 7   July 2015
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Figure 5. Both the selenium-rich region and the putative antioxidant domain of SEPP1 protect from inflammatory tumorigenesis. (A) Quantification of
colonic selenium in WT (n = 6) and Sepp1Δ240–361/Δ240–361 (n = 6) mice and (B) number of tumors per mouse (16, WT; 15, Sepp1Δ240–361/Δ240–361). *P < 0.05, ***P < 0.001,
2-tailed unpaired t test. (C) Percentage of total tumors per genotype with either high-grade dysplasia (HGD) or low-grade dysplasia (LGD) (n = 15 per group,
***P < 0.001, χ2 contingency analysis) and representative images from tumors of the given genotypes (original magnification, ×40). Scale bar: 200 μm. (D)
Quantification of intratumoral proliferation, as measured by Ki67+ cells per tumor HPF (12, WT; 17, Sepp1Δ240–361/Δ240–361). (E) Crypt DNA damage, as measured by
8-hydroxyguanine+ cells per crypt averaged from 20 crypts within each mouse (8, WT; 9, Sepp1Δ240–361/Δ240–361). (F) Intratumoral DNA damage, as measured by
8-hydroxyguanine+ cells per tumor HPF (8, WT; 17, Sepp1Δ240–361/Δ240–361). (G) Number of tumors and (H) average tumor size within either WT (n = 12) or Sepp1U40S/U40S
(n = 16) mice. (I) Quantification of crypt proliferation, as measured by Ki67+ cells per crypt averaged from 20 crypts within each mouse (8, WT; 8, Sepp1U40S/U40S);
(J) intratumoral proliferation, as measured by Ki67+ cells per tumor HPF (11, WT; 19, Sepp1U40S/U40S); (K) crypt DNA damage, as measured by 8-hydroxyguanine+
cells per crypt averaged from 20 crypts within each mouse (8, WT; 8, Sepp1U40S/U40S); and (L) intratumoral DNA damage, as measured by 8-hydroxyguanine+ cells
per tumor HPF (9, WT; 8, Sepp1U40S/U40S). *P < 0.05, **P < 0.01, ***P < 0.001, 2-tailed unpaired t test.
2652
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Figure 6. Sepp1 haploinsufficiency-driven CAC persists in mice
maintained on normal selenium
diets. (A) Endoscopic images of
WT and Sepp1+/– colons after the
second cycle of DSS administration.
(B) Quantitative assessment of
endoscopic tumor burden (11, WT;
13, Sepp1+/–). **P < 0.01, 2-tailed
unpaired t test. (C) Gross representative images of tumors (D) and
tumor counts at necropsy (11, WT;
13, Sepp1+/–). ***P < 0.001, 2-tailed
unpaired t test. (E) Tumor size distribution. *P < 0.05, unpaired t test
with Welch’s correction. (F) Survival
analysis of AOM/DSS-treated mice
maintained on the indicated diets.
***P < 0.001, unpaired t test with
Welch’s correction.

absence of SEPP1 increases baseline stem phenotypes and proliferation and compromises the antioxidant potential of enteroids.
These data are particularly compelling, because they indicate an
epithelial cell–autonomous role for SEPP1 in processes that would
likely contribute to tumorigenesis in CAC, a cancer characterized
by increased microenvironmental oxidative stress.
WNT signaling and oxidative stress gene signatures are altered in
Sepp1–/– epithelium. Enteroids rely on the addition of growth factors
EGF, noggin, and R-spondin for growth and differentiation (47). As
Sepp1–/– enteroids demonstrate increased stem cell properties and
fitness, we next determined growth factor dependency of Sepp1–/–
enteroids. Depletion of EGF, noggin, and R-spondin resulted in
similar decreases in survival in all 3 genotypes, indicating that all 3
pathways are important for enteroid persistence (Figure 8A).
In order to acquire an unbiased understanding of transcriptome changes within tumors of Sepp1–/– mice, we performed
RNA sequencing (RNAseq) analysis of tumors isolated from WT
and Sepp1–/– mice subjected to the AOM/DSS protocol. Ingenuity
pathway analysis indicated that the WNT pathway was among
the most significantly altered canonical pathways (Supplemental
Figure 8), as Sepp1–/– tumors demonstrated increases in Tgfbr3,
Appl2, Sfrp4, Sfrp5, and Cdh2 expression, among other abnormalities (Table 1 and Supplemental Figure 9). As further validation of
altered WNT signaling in these tumors, protein analysis demonstrated increased expression of the WNT targets LEF-1, cyclin D1,

and MMP-7 upon loss of Sepp1
expression (Figure 8B). We next
determined whether SEPP1 loss
influenced production of other
oxidative defense genes. First,
we tested for compensation by
other selenoproteins at the RNA
level and did not observe differences in their message between
WT and Sepp1–/– tumors. We did,
however, note significant alterations in several cytochrome
P450 gene family members as
well as β-hydroxysteroid dehydrogenase genes (Supplemental Figure 7), suggesting that other antioxidant genes are upregulated in
an attempt to compensate for SEPP1 loss.

Discussion

The efficacy of antioxidants as chemopreventive agents of malignancy in the general population has been disappointing. However,
most studies have been conducted in the setting of relatively normal selenium levels, which ensures sufficient production of the
majority of selenoproteins. Patients with IBD are reported to be
selenium deficient, potentially skewing selenoprotein production.
Our findings suggest that modifying production of selenoproteins
(i.e., SEPP1) in patients with IBD may impact cancer risk. Here,
we show that reduced levels of a major selenoprotein, SEPP1,
result in increased colonic epithelial stem cell properties, such as
increased branching and increased presence of stem spheroids as
well as increased WNT signaling. Reduced expression of SEPP1
also results in increased DNA damage in response to oxidative
stress. These SEPP1-dependent phenotypes ultimately contribute
to an increase in inflammatory tumorigenesis upon loss of either
the redox-active site or the selenium transport domain of SEPP1
via its effects on the tumor microenvironment and preservation of
genomic integrity. These data establish a critical role for SEPP1 in
intestinal biology, homeostasis, injury response, preservation of
genomic integrity, and inflammatory carcinogenesis.
jci.org   Volume 125   Number 7   July 2015
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Table 1. Select genes from the WNT signaling pathway that are
overexpressed in Sepp1–/– tumors
Gene symbol
Tgfbr3
Appl2
Sfrp4
Sfrp5
Cdh2

Gene name

Fold change

P value

Transforming growth factor β-3
Adapter protein containing PH domain, PTB
domain, and leucine zipper motif 2
Secreted frizzled-related protein 4
Secreted frizzled-related protein 5
Cadherin-2

3.4
2.4

5.00E-05
0.0015

2.7
2.9
2.1

0.00015
5.00E-05
0.00035

Ingenuity pathway analysis of Sepp1–/– tumor RNAseq data relative to
WT data is shown.

Induction of several signaling pathways, including NRF2 (11)
and WNT (10), has been linked to selenium depletion, and there
is little known about the contribution of SEPP1 to the observed
alterations in these pathways. We therefore performed an unbiased RNAseq analysis of tumors from WT and Sepp1–/– mice after
subjecting them to the AOM/DSS protocol. Among the most
severely altered pathways in response to SEPP1 loss was the WNT
pathway. While genes were both upregulated and downregulated
in this pathway, some of particular importance included modulators of WNT signaling, Sfrp4 and Sfrp5; the transcriptional effector
Lef (also known as Tcf); and the WNT target Mmp7, which we also
validated at the protein level. Genes that demonstrated increased
expression included those coding for the TGF-β receptor, N-cadherin, and the liver receptor homolog-1 (LRH-1), which is important for maintaining stem cell pluripotence during development
(53). Importantly, ingenuity pathway analysis identified the
WNT/β-catenin signaling pathway as being stimulated in Sepp1–/–
tumors. This is of particular importance because SEPP1 is a selenium transporter and selenium deficiency leads to an increase in
WNT signaling, suggesting that the selenium transport function of
SEPP1 may contribute to WNT modulation.
The literature has extensively implicated selenium in the
modulation of immune processes, particularly in relation to macrophage activity (54–56). We noted an increase in M2 polarized
macrophages in tumors of AOM/DSS-treated Sepp1+/– mice and
hypothesized that this was due to an effect of SEPP1 on macrophage polarization. Isolation of bone marrow macrophages from
Sepp1+/– mice and subsequent polarization with either IFN-γ and
LPS (M1) or IL-13 (M2) resulted in deficits in expression of the M1
markers Inos and Il1b and increased expression of the M2 marker
Ym1. This altered polarization may contribute to tumorigenesis by
altering the tumor microenvironment in Sepp1+/– mice. As such,
SEPP1 may reduce inflammatory tumorigenesis by attenuating
proinflammatory immune cell activation. This is especially important to note when considering the potential positive impact of selenium supplementation on patients with nutritional deficiencies
due to diseases, such as IBD.
The influence of plasma SEPP1 on delivery of selenium to target tissues has been extensively studied (36, 57, 58). Our enteroid
studies demonstrate a role for tissue-produced SEPP1 in intestinal biology, as loss of intestinal epithelial cell–autonomous Sepp1
affects cellular growth, differentiation, and response to ROS.
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Because it is a secreted protein, we hypothesize that SEPP1 provides localized antioxidant benefit to the proximate epithelial
microenvironment. It was recently shown that SEPP1 antioxidant
capacity is due, at least in part, to its ability to act as a substrate for
thioredoxin reductase-1, which catalyzes NADPH oxidation (59).
From these studies, we postulate that extracellular SEPP1 within
the near-cell environment may be cooperating with intracellular
selenoproteins, such as thioredoxin reductase-1, Gpx2, and Gpx4,
to protect the epithelium from oxidative damage.
Whether selenium supplementation is of potential value
in reducing cancer risk has been studied. The US case-control
SELECT study did not demonstrate any clear association between
serum selenium levels and the risk of recurrent CRC (60), and a
meta-analysis of intervention trials concluded that oral administration of antioxidants, including selenium, was not effective in
preventing colorectal neoplasia in the general population (61). A
major limitation of these studies, however, was patient selection,
as patients in both studies had near-normal selenium levels. Our
data suggest that targeted supplementation in populations known
to be selenium deficient might be an effective prevention strategy.
Patients with IBD are selenium deficient, as measured by both
plasma selenium and SEPP1 levels (62). Furthermore, the plasma
concentration of SEPP1 is reduced 53% in patients with Crohn’s
disease compared with that in healthy controls (63). This suggests
that patients with IBD are selenium deficient to such an extent
that selenium supplementation might increase SEPP1 levels and
subsequently reduce risk of CAC arising from IBD. Indeed, in line
with the idea of a protective role for selenium supplementation,
our study demonstrated a significant survival benefit in cohorts of
mice that were on high selenium diet in comparison to those on
normal selenium diet when subjected to an AOM/DSS inflammatory carcinogenesis protocol.
Importantly, several SNPs have been identified in SEPP1 that
might contribute to decreased expression in tumors. For instance,
SNPs in SEPP1 are associated with decreased plasma SEPP1 in
men and increased prostate cancer risk (40, 64). Furthermore, 4
SEPP1 variants have been significantly associated with advanced
colorectal adenoma risk, including the variant SEPP1 -4166G,
which exists within the promoter region, 2 loci in the 3′ region
of SEPP1, and a third locus in the 3′ region of SEPP1, which is
inversely associated with risk of colorectal adenoma (22). Additionally, genetic instability has been observed within the (T)17
repeat motif within the SEPP1 promoter in CRC to the mutator
phenotype. Thus, this SEPP1 repeat structure may be of functional
relevance to SEPP1 gene expression and thus modify tumorigenesis (65). A mechanism by which some of these polymorphisms
may alter SEPP1 status is by either altering expression or proportions of SEPP1 isoforms. Several functional polymorphisms in the
SEPP1 gene have been shown to influence isoform expression, and
it is thought that increased expression of the 60-kDa isoform of
SEPP1 may increase selenoprotein synthesis and decrease CRC
risk (66). Thus, genotyping of SEPP1 in patients with CAC may
indicate increased responsiveness to selenium supplementation.
In conclusion, we demonstrate a cell-autonomous role for
SEPP1 in the intestinal epithelium and that its reduction, in vivo,
augments inflammatory carcinogenesis. These in vivo effects
occur via independent enzymatic and transport activities. Our
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Figure 7. Sepp1–/– enteroids display increased stem cell characteristics as well as ROS production, proliferation, and decreased survival after oxidative
stress. (A) Sepp1 mRNA expression in tissue isolated from WT mice (n = 3 per group). Fold change expression normalized to Gapdh and relative to colonic
Sepp1 expression. ***P < 0.001, 1-way ANOVA, Newman-Keuls multiple comparison test. (B) Percentage of surviving enteroids 1 day after plating, percentage of branching enteroids and stem spheroids counted 3 days after plating, and average number of branches per branching enteroid at 4 days after plating
(n = 4 per group per experiment). *P < 0.05, **P < 0.01, ***P < 0.001, 2-tailed unpaired t test. (C) ROS quantification by carboxy-H2DCFDA staining intensity,
as measured 2 hours after treatment with H2O2. Fold change in intensity relative to WT enteroids treated with 0 μM H2O2 (n = 4 per group). Representative
images of the single carboxy-H2DCFDA channel and merged carboxy-H2DCFDA and TO-PRO3 channels in WT and Sepp1–/– enteroids treated with either 0
μM or 800 μM H2O2 (original magnification, ×100). *P < 0.05, 1-way ANOVA, Newman-Keuls multiple comparison test. (D) Proliferation, as determined by
EdU+ cells per crypt area within WT and Sepp1–/– enteroids after 2 hours of treatment with either 0 μM or 800 μM H2O2 (n = 4 per group with analysis of 10
enteroids per genotype) and representative images of EdU staining in WT and Sepp1–/– enteroids after treatment with either 0 μM or 800 μM H2O2 (original
magnification, ×100). *P < 0.05, **P < 0.01, 1-way ANOVA, Newman-Keuls multiple comparison test. (E) Survival curves for WT, Sepp1+/–, and Sepp1–/–
enteroids after daily treatment with 400 μM H2O2.

studies establish a critical role for SEPP1 in intestinal biology,
homeostasis, injury response, preservation of genomic integrity,
and inflammatory carcinogenesis and suggest that SEPP1 could
serve as a therapeutic target in the prevention of CAC.

Methods

Murine carcinogenesis protocols. Sepp1–/– mice exhibit decreased survival on standard chow diet (42) and require selenium supplementation. Therefore, these mice were fed Torula yeast-based diets supplemented with 1.0 mg selenium (sodium selenite was used) per kg.
Accordingly, to properly control the experiment, WT and Sepp1+/– mice
were also maintained on an identical diet. In a separate experiment,

WT and Sepp1+/– mice were maintained on a normal selenium Torula
yeast-based diet (0.25 mg selenium [sodium selenite was used] per
kg). These diets were prepared and pelleted to our specifications
(42) by Harlan-Teklad. For AOM only experiments (Figure 1A), 8- to
12-week-old C57BL/6 WT (n = 4), Sepp1+/– (n = 4), or Sepp1–/– (n = 4) mice
(17, 18) were injected with 12.5 mg/kg AOM (Sigma-Aldrich) intraperitoneally. Mice were monitored for tumor burden by endoscopy once
per month for 6 months and sacrificed 180 days after AOM injection.
For chronic DSS experiments, 8- to 12-week-old C57BL/6 WT (n = 7),
Sepp1+/– (n = 10), or Sepp1–/– (n = 10) mice (17, 18) were subjected to three
5-day cycles of 3% DSS ad libitum, with each cycle being followed by
a 16-day recovery period (Figure 1B). Mice were monitored for colonic
jci.org   Volume 125   Number 7   July 2015
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Figure 8. WNT signaling plays a pivotal role in the Sepp1–/– phenotype. (A) Survival curves in response to growth factor depletion in WT, Sepp1+/–, and
Sepp1–/– enteroids. (B) Quantification of WNT proteins LEF-1, cyclin D1, and MMP-7 normalized to β-actin. Quantification is shown as fold change relative
to WT and representative images of blots from 3 individual tumors from each genotype. *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA, Newman-Keuls
multiple comparison test.

injury by endoscopy 4 days into the recovery period after each DSS
administration. Injury was evaluated based on the MEICS scoring
system, which grades mucosal thickening, vasculature pattern, granularity, exudate, and stool consistency (67). For AOM/DSS protocols,
8- to 12-week-old C57BL/6 WT (n = 13), Sepp1+/– (n = 9), or Sepp1–/–
(n = 11) mice (17, 18) (constitutional knockout experiment with mice fed
1.0 mg selenium per kg diet); WT (n = 16) or Sepp1+/– (n = 17) mice (constitutional knockout experiment with mice fed 0.25 mg selenium per
kg diet); WT (n = 16) or Sepp1Δ240–361/Δ240–361 (n = 14) mice (36) (truncation
experiments); and WT (n = 12) or Sepp1U40S/U40S (n = 15) (20) mice (redox
motif mutant experiments) (Table 2) were injected with 12.5 mg/kg
AOM (Sigma-Aldrich) intraperitoneally. Three days after injection,
the animals were started on the first of 3 cycles of 3% DSS ad libitum.
Each cycle lasted 5 days and was followed by a 16-day recovery period.
During each cycle of recovery, colonoscopy was performed to assess
injury, tumor multiplicity, and grade (67). All mice were sacrificed on
day 70, with the exception of cohorts maintained on 0.25 mg selenium
per kg diet, which were sacrificed on day 52 due to increased mortality following the third cycle of DSS. All tumor counts and measurements were performed in a blinded fashion under stereo-dissecting
microscopy. Histologic analysis was performed in a blinded fash2656
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ion for severity of inflammation (68) and dysplasia on H&E-stained
“Swiss-rolled” colons by a gastrointestinal pathologist in house.
Immunohistochemistry and immunofluorescence staining. For SEPP1
and phalloidin staining, colons and small intestines were embedded in
OCT media and flash frozen in liquid nitrogen. Five-micrometer sections were cut and SEPP1 staining was performed as described previously (69). For all other staining, standardized protocols were followed
to ensure the integrity of the samples for immunohistochemistry/
immunofluorescence applications. In brief, immediately upon sacrifice, the colons were harvested, flushed with ice-cold PBS, Swiss rolled
without delay, and fixed in fresh neutral buffered 10% formalin, which
was subsequently exchanged for 70% EtOH. Processing was performed at the Vanderbilt University Translational Pathology Shared
Resource. Five-micrometer sections of paraffin-embedded colons
were cut, and H&E staining was performed. For immunohistochemistry, cut sections were dewaxed, hydrated, and quenched of endogenous peroxidase activity with 0.03% hydrogen peroxide in methanol.
Antigen retrieval was conducted using Antigen Unmasking Reagent
(Vector Laboratories Inc.) according to the manufacturer’s instructions. After blocking, primary antibody was added (α-Ki67 [NeoMarkers], 1:1,000; α-ARG1 [Santa Cruz], 1:500; α–IL-1β [R&D Systems],
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Table 2. The genotypes of mice subjected to the AOM/DSS
protocol and the symbols used for each genotype
Nomenclature
WT

Mouse description
WT N10 C57BL/6

+/–

Sepp1

Heterozygous SEPP1 knockout (C57BL/6)

Sepp1–/–

Homozygous SEPP1 knockout (C57BL/6)

Sepp1Δ240–361/Δ240–361
Sepp1U40S/U40S

Homozygous deletion of SEPP1 amino acids 240–361 (C57BL/6)
Homozygous point mutation of position 40 selenocysteine
to serine in SEPP1 (C57BL/6)

1:40; α-F4/80 [ABd Serotec], 1:1,000; α-8-OHdG [Santa Cruz], 1:500)
and incubated overnight at 4°C. Isotype-matched antibodies were
included as negative controls. Identification of intratumoral apoptotic
cells was conducted using the ApopTag Plus Peroxidase In Situ Apoptosis Kit (Chemicon) according to the manufacturer’s protocol. Control slides were obtained by omitting the terminal transferase enzyme.
For immunofluorescence staining of proliferation, macrophages, and
DNA damage, slides were counterstained and mounted with ProLong
Gold antifade, including DAPI (Invitrogen). Apoptosis, proliferation,
DNA damage, and M1 and M2 macrophage indices were generated by
counting either the number of positive cells per HPF (×40 objective)
within each tumor or the number of positive cells per crypt in 20 crypts
per mouse by a blinded observer. The average score was then calculated for each Swiss-rolled colon.
Colonic selenium measurements. The determination of colonic selenium was carried out using a modification of the fluorometric assay
of Koh and Benson (70) developed by Sheehan and Gao (71). Briefly,
tissue was digested in nitric and perchloric acids and, after adjustment
of pH, selenium (as selenite) was complexed with diaminonaphthalene. Selenium-diaminonaphthalene was extracted into cyclohexane,
and fluorescence was measured in a Perkin-Elmer LS 55 fluorometer
as described previously (58).
Western blot analysis of apoptosis and WNT pathway proteins. Flashfrozen sections of colon (n = 6 for each genotype) were lysed in RIPA
buffer, including 1× protease inhibitor cocktail (Sigma-Aldrich), using
a rotor homogenizer (Janke & Kunkel IKA Labortechnik Ultra-Turrax
T25). Protein quantification was performed using a Pierce BCA Protein Assay Kit (Thermo) according to the manufacturer’s instructions.
Samples were suspended in loading buffer, boiled, and 40 μg of protein was run on an SDS-PAGE gel for immunoblotting. The Apoptosis
Antibody Sampler (Mouse Preferred) Kit (9930, Cell Signaling Technology) and the WNT Signaling Antibody Sampler Kit (2915, Cell Signaling Technology) were used according to the manufacturer’s protocol. Quantification was performed using Odyssey Imaging Software
and normalized either to total caspase or β-actin.
Bone marrow macrophage polarization and analysis. Bone marrow
macrophages were isolated and activated as has been previously published (72, 73). For the production of classically activated M1 macrophages, bone marrow macrophages were primed with 150 U/ml IFN-γ
for 6 hours and subsequently stimulated with 10 ng/ml LPS. For the
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production of alternatively activated M2 macrophages, bone marrow
macrophages were treated with 20 U/ml IL-13 for 12 hours. RNA was
isolated using the RNEasy Mini Kit (Qiagen). 1 μg RNA was used to
perform reverse transcription PCR using the iScript cDNA Synthesis
Kit (Bio-Rad). 1 μl cDNA was used for qRT-PCR analysis of Inos (BioRad 100-31225), Il1b (RealTimePrimers.com VMPS-3072), and Ym1
(Bio-Rad 100-31225).
Plasma SEPP1 protein determination. Plasma SEPP1 was measured by ELISA (36). Plasma samples were diluted in PBS with 0.05%
Tween-20 containing 2% rat plasma cleared of SEPP1 by monoclonal
antibody 8F11 as described previously (74).
Small intestinal organoid culturing. Six centimeters of the distal
small intestine were dissected, flushed with ice-cold PBS, dissected
into 1-cm pieces, suspended in 5 ml ice-cold PBS, and vortexed
for 3 seconds. PBS was removed with a pipettor, and the wash was
repeated. Tissue was transferred to 5 ml chelation buffer (1 mM
EDTA, made fresh in DPBS) and rocked for 10 minutes at 4°C prior to
washing twice with 10 ml PBS. 5 ml PBS was added and shaken gently for 2 minutes. The supernatant from the first shake was poured
off. 5 ml PBS was added, and the shake was repeated for 2 minutes
before the supernatant was poured off. 5 ml fresh chelation buffer
was added, and chelation was performed for 10 minutes at 4°C with
rocking. Crypts were filtered through a 70-μm filter into a prechilled
50-ml tube. The filter was rinsed with 5 ml cold shaking buffer (PBS
with 43.3 mM sucrose and 54.9 mM sorbitol). Complete crypts were
counted and enough volume for 1,200 crypts was transferred to a
prechilled 5-ml round-bottomed tube. Crypts were centrifuged at
150 g for 10 minutes at 4°C. Shaking buffer was aspirated, and crypts
were resuspended in 50 μl Matrigel (BD Bioscience 356237) per well,
containing 50 ng/ml EGF (2028-EG-200, R&D Systems), 100 ng/ml
Noggin (1967-NG-025/CF, R&D Systems), 500 ng/ml R-Spondin
(3474-RS-050, R&D Systems), and 200 ng/ml WNT3a (GF-160,
Millipore). Matrigel was overlaid with 500 μl Minigut culture media
(Advanced DMEM/F12 [12634-010, Invitrogen], l-Glutamine
[25030, Invitrogen], Pen-Strep [15140-148, Invitrogen], HEPES
[25-060-CI, Mediatech], N2 Supplement [390155, R&D Systems],
B27 Supplement [17504044, Invitrogen]). Every 4 days, media were
replaced with fresh Minigut media plus growth factors.
Whole-mount carboxy-H2DCFDA enteroid staining. Enteroids
were grown for 4 days after plating. The morning of hydrogen peroxide treatment, enteroid media were replaced with fresh Minigut
media. 0 μM, 400 μM, or 800 μM hydrogen peroxide was added
directly to media. Two hours after hydrogen peroxide treatment,
growth media were removed from cells. Cells were treated with
prewarmed DPBS containing either the probe carboxy-H2DCFDA
(mp-36103, Invitrogen) or, as a negative control, carboxy-DCFDA
to provide a final working concentration of 5 mM. Enteroids were
incubated at 37°C in a cell culture incubator for 1 hour. Loading
buffer was removed, and cells were returned to prewarmed Minigut
media. Cells were incubated at 37°C for 15 minutes. Media were
removed, and enteroids were fixed overnight at 4°C in 2% formaldehyde with gentle rocking. Fixative was removed, and enteroids were
washed twice with DPBS. Enteroids were imaged with a LSM 510
confocal microscope using the same specifications for imaging of all
enteroids. ROS were quantified as staining intensity using ImageJ
Image Analysis software. The graph represents the fold change
intensity relative to WT enteroids treated with 0 μM hydrogen
jci.org   Volume 125   Number 7   July 2015
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peroxide (Figure 7C). Error bars represent the SEM for 3 separate
experiments performed in duplicate.
Whole-mount enteroid proliferation staining. Proliferation was
determined using the Click-iT EdU cell proliferation assay (C-10337,
Invitrogen) according to the manufacturer’s instructions. Enteroids
were grown to 4 days after plating. Enteroid media were replaced with
fresh Minigut media, and either 0 μM or 800 μM hydrogen peroxide was added directly to media. Two hours after hydrogen peroxide
treatment, media were replaced with fresh Minigut media and a 10 μM
working solution of EdU was added to each well of the plate. Enteroids
were incubated for 15 minutes under normal growth conditions. After
incubation, media were removed and 1 ml of 2% formaldehyde in PBS
was added to each well and incubated overnight at 4°C. The fixative
was removed and enteroids were washed twice with 1 ml of 3% BSA
in PBS. Wash buffer was removed, and 1 ml of 0.5% Triton X-100 in
PBS was added to each well and incubated at room temperature for
20 minutes. Click-iT reaction cocktail was prepared, and 0.5 ml was
added to each well. The wash solution was removed, and enteroids
were stained with TO-PRO-3 (1:500 in PBS for 15 minutes at room
temperature). Enteroids were imaged with a LSM 510 confocal microscope using the same specifications for imaging of all enteroids. Proliferation was quantified as EdU+ cells per crypt area where crypt area
was determined using ImageJ Image Analysis software. The graph
represents the fold change intensity relative to WT enteroids treated
with 0 μM hydrogen peroxide (Figure 7D). Error bars represent the
SEM for 3 separate experiments performed in duplicate.
RNAseq assay and analysis. Tumors were dissected from WT
and Sepp1–/– mice, and RNA was isolated using the RNEasy Mini Kit
(Qiagen). RNA integrity was determined using the Experion RNA StdSens Analysis Kit (Bio-Rad). All RNA samples had RNA integrity numbers >8 and were deemed suitable for analysis. Initial raw sequencing
data were aligned to reference mouse genome (mm10) using TopHat
(version 2.0.8) software with default parameters (75). The Cuffdiff
software (version 2.1.1) was used to estimate read count for expression
of each gene and to detect differentially expressed genes. For countbased gene expression data, Cuffdiff uses the beta negative binomial
model for each gene in each condition in order to estimate the null
distribution of its log fold change under the null hypothesis (76). The
P values from Cuffdiff were adjusted by Benjamini and Hochberg’s
method to control false discovery rate (77).
Statistics. Analyses comparing 2 groups were analyzed using the
2-tailed Student’s t test. One-way ANOVA and Newman-Keuls posttest were used to compare multiple groups. Data are presented as
the mean ± the SEM in bar graphs, and a line identifying the mean
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is shown when all data points are plotted. Percentages of mice displaying altered dysplasia grade were determined using χ2 contingency
analysis for each grade. All of these analyses were performed using
GraphPad Prism 5.0c.
Study approval. This study was performed in strict accordance with
the recommendations in the Guide for the Care and Use of Laboratory
Animals (8th ed. The National Academies Press. 2011.). The study protocol was approved by the Institutional Animal Care and Use Committee at Vanderbilt University (protocol no. M/10-355).
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